GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Sign Up to like & getrecommendations! Published in 2019 at "European urology oncology"
DOI: 10.1016/j.euo.2018.08.003
Abstract: BACKGROUND Tumor intraductal carcinoma/cribriform architecture (IDC/C) is associated with an unfavorable prognosis and biochemical recurrence (BCR) in prostate cancer (PCa). Up to 70% of PCa patients are IDC/C-negative, but it is estimated that 20% of… read more here.
Keywords: bcr; cancer; methylation; biochemical recurrence ... See more keywords